tbuckley/cabot-search huggingface dataset:
Women's Health
Authors: Roberta Ness
Journal: Annals of Internal Medicine (2001)

Medical Writings: Book Notes2 October 2001Women's HealthRoberta Ness, MD, MPHRoberta Ness, MD, MPHUniversity of Pittsburgh, Pittsburgh, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-7-200110020-00024 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Thiedke CC, Rosenfeld JA, eds. 162 pages. Philadelphia: Lippincott Williams & Wilkins; 2000. $29.95. Order phone 800-638-0672.Field of Medicine: Women's health.Format: Softcover book.Audience: Family physicians and internists.Purpose: A how-to, brief presentation of diagnosis and treatment of several common problems for which women seek primary care.Context: The first several chapters cover gynecologic concerns. These are followed by ready reference overviews of heart disease, weight issues, mood disorders, sexual issues, arthritis, osteoporosis, and fatigue syndromes. Each section includes broad discussion of diagnosis and prevention or treatment.Highlights: Simple charts and algorithms make for easy reading. Some chapters, ... Author, Article, and Disclosure InformationAffiliations: University of Pittsburgh, Pittsburgh, Pennsylvania. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 2 October 2001Volume 135, Issue 7Page: 556KeywordsCardiovascular therapyInterstitial lung diseasesMood disordersMutationObstetrics and gynecologyOsteoporosisOvarian cancerSexually transmitted diseasesSmoking preventionSoftware tools ePublished: 2 October 2001 Issue Published: 2 October 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Cohort study of oligorecurrent prostate cancer patients: Oncological outcomes of patients treated with salvage lymph node dissection via PSMA radioguided surgery.
Authors: Tobias Maurer, Mehrdad Mehdi Irai, Isabel Rauscher, Ricarda Simon, Matthias Eiber, Fijs WB van Leeuwen, Pim van Leeuwen, Lars Budaeus, Thomas Steuber, Markus Graefen, Pierre Tennstedt, Matthias Heck, Thomas Horn, Sophie Knipper
Journal: Journal of Clinical Oncology (2022)

106 Background: Prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) allows detection of small and/or atypically localized metastatic prostate cancer (PCa) lesions. In a subset of patients with recurrent oligometastatic PCa salvage surgery with PSMA-targeted radioguidance (PSMA-RGS) may be of value. We aimed to evaluate the oncological outcomes of salvage PSMA-RGS for oligorecurrent PCa and determine predictive preoperative factors of improved outcomes. Methods: In this cohort study within two tertiary care centers, patients with biochemical recurrence (BCR) after radical prostatectomy (RP) and imaging with PSMA PET receiving salvage PSMA-RGS between 2014 and 2020 were analyzed. Kaplan-Meier and multivariable Cox regression models adjusted for various parameters were used to test for BCR-free survival (BFS) and therapy-free survival (TFS) differences. Postoperative complications were classified according to Clavien-Dindo. Results: Overall, 364 patients were assessed. At PSMA-RGS, median (IQR) age and preoperative PSA was 67 (61-71) years and 1.0 (0.5-1.9) ng/ml. Metastatic soft-tissue lesions were removed in 356 (94.4%) patients. Within three months from surgery, 25 (6.6%) patients suffered from Clavien-Dindo complications grade III-IV. During follow-up, 235 patients experienced BCR and 129 patients received further therapy. Median follow-up for patients who did not experience BCR and who did not receive further therapy was 11.1 months and 10.5 months, respectively. Median (IQR) BFS and TFS was 7.8 (5.4-10.9) and 34.9 (24.7-43.5) months. At two years of follow-up, BFS rate was 31.9% and TFS rate was 56.6%. In multivariable analyses, higher preoperative PSA (HR: 1.06), higher number of PSMA-avid lesions on preoperative imaging (HR: 1.2) and multiple (pelvic plus retroperitoneal) localizations (HR: 1.7), as well as retroperitoneal localization (HR: 2.0) of lesions in PSMA PET imaging were independent predictors of BCR after PSMA-RGS. Limitations are the retrospective design and lack of a control group. Conclusions: As salvage surgery in oligorecurrent PCa currently constitutes an experimental treatment approach careful patient selection is mandatory based on life expectancy, low PSA values and low number of PSMA PET avid lesions located in the pelvis. Further studies are needed to confirm our findings and define the oncological value of salvage surgical procedures in oligorecurrent PCa.
TRK inhibition for pediatric and adult central nervous system tumors: Early promise and future questions
Authors: Ross Mangum, Donald Williams Parsons
Journal: Neuro-Oncology (2022)

Central nervous system (CNS) tumors are the most common cause of cancer-related death in children. Despite significant treatment advances, survival rates for several tumor types (including diffuse midline glioma and other high-grade gliomas, as well as most recurrent tumors) remain poor, and current multimodal therapies, including surgery, radiation therapy, and cytotoxic chemotherapy carry a high risk of treatment-related morbidities. There is therefore a critical need to translate recent discoveries on the biological and genetic basis of pediatric CNS tumors into improvement in clinical care for these patients. Comprehensive analysis (including genome, transcriptome, and epigenome) of diverse CNS tumors has led to a heightened understanding of the spectrum and frequency of disease-specific tumorigenic genetic events underlying common pediatric tumor types, including low-grade glioma,1 high-grade glioma,2 medulloblastoma,3 and ependymoma.4 These discoveries have led to improved classification of pediatric CNS tumors through definition of key molecular events and are being successfully incorporated into the care of patients with selected tumor types. As one example, recent reports have confirmed the activity of the MEK inhibitor selumetinib for patients with both neurofibromatosis type 1 (NF1)-associated and non-NF1-associated low-grade glioma,5,6 establishing selumetinib as a therapeutic option for these patients.
Wide-tunnel endoscopic submucosal dissection with clip-and-line traction for large circumferential esophageal neoplasm
Authors: Xuelian Li, Zhongshang Sun, Liansong Ye, Zhiying Gao, Qilong Wang, Feng Pan
Journal: Endoscopy (2022)

Endoscopic submucosal dissection (ESD) has become the main method for management of superficial esophageal lesions [1]. However, it remains technically challenging and time-consuming for circumferential lesions [2]. The strategies reported for circumferential diseases have operational complexity [2] [3]. Herein, we present an ESD method involving a single, wide tunnel and clip-and-line traction for resection of a large circumferential esophageal neoplasm.
Abstract 17197: Preventive Multivessel Percutaneous Coronary Intervention in St Segment Myocardial Infarction is Associated With Worse Outcomes Than Infarct Related Artery Intervention Alone - A Propensity Matched Comparison
Authors: Byomesh Tripathi, Shilpkumar Arora, Varun Kumar, Purnima Sharma, Abhishek Mishra, Varunsiri Atti, Shikha Malhotra, Nileshkumar J Patel, Abhishek Deshmukh, Radha Gopalan
Journal: Circulation (2018)

Introduction: Recent trials have suggested potential benefits of performing multivessel percutaneous coronary intervention (MVPCI) on non-infarct related artery (non-IRA) in ST-segment elevation myocardial infarction (STEMI) patients with multivessel disease. Methods: National Readmissions Database (NRD) 2010-14 was utilized to select study cohort. Appropriate International Classification of Diseases, 9th Revision (ICD-9-CM) diagnostic and procedural codes were utilized to identify STEMI patients undergoing multivessel PCI and infarct-related artery only PCI (IRA-PCI). Propensity score matched cohorts using greedy matching algorithm were generated for comparison of outcomes. Results: We identified 116592 IRA-PCI (83.97%) and 22257 MVPCI (16.03%) cases. With 1:3 propensity matched cohorts accounting for confounders such as age, gender, race and comorbidities, in comparison to IRA-PCI, MVPCI patients have higher 30-day readmission rate (10.40% vs 9.40%, p=0.001), in-hospital mortality (1.96% vs 1.57%,p&lt;0.001), mechanical circulatory support utilization (4.27 vs 2.44%,p&lt;0.001) as well as higher complication including vascular (0.51% vs 0.28%, p&lt;0.001), cardiac (5.97% vs 3.97%, p&lt;0.001), respiratory (4.89% vs 4.02%,p&lt;0.001), neurologic complications (0.77% vs 0.58%,p=0.003), major bleeding (1.01% vs 0.79%, p=0.002) and cardiac arrest(3.48% vs 3.17%, p=0.027). We also noted higher cost of care ($27100 vs $20900, p&lt;0.001) and length of stay (3.8 days vs 3.4 days, p&lt;0.001) in MVPCI group compared to IRA-PCI group. Conclusions: We noted higher 30- day readmission rate, in-hospital mortality, complications and resource utilization with MVPCI compared to IRA-PCI approach among STEMI patients which further demands large-scale randomized control trials to determine the utility of MVPCI in the “real world”.
TCTAP A-152 Comparison of Zotarolimus-Eluting and Everolimus-Eluting Stents in Patients with Multi-Vessel Coronary Artery Disease
Authors: Cheol Hyun Lee, Seung-Jung Park, Seong-Wook Park, Cheol Whan Lee, Young-Hak Kim, Seung-Whan Lee, Duk-Woo Park, Soo-Jin Kang, Jung-Min Ahn, Pil Hyung Lee, Se Hun Kang, Min Soo Cho, Jae Seok Bae, Yu Na Kim, Sung Han Yoon, Do-Yoon Kang, Mineok Chang
Journal: Journal of the American College of Cardiology (2016)
Genomic classification of clinically advanced major genito-urinary cancers (GUca) based on methylthioadenosine phosphorylase (<i>MTAP</i>) genomic loss.
Authors: Philippe E. Spiess, Andrea Necchi, Petros Grivas, Gennady Bratslavsky, Joseph M Jacob, Oleksandr Kravtsov, Richard S.P. Huang, Vamsi Parini, Brennan Decker, Douglas I. Lin, Dean C. Pavlick, Natalie Danziger, Jeffrey S. Ross
Journal: Journal of Clinical Oncology (2022)

164 Background: Novel treatments for clinically advanced GUca including castrate resistant prostate ca (PC), bladder urothelial ca (BUC) and clear cell renal ca (ccRCC) are widely needed. Recently, the targeting of cancer cells with arginine accumulation caused by MTAP loss has emerged as a new synthetic lethality-based anti-cancer program. Methods: 8,436 mCRPC, 2,683 BUC and 841 ccRCC underwent hybrid-capture based comprehensive genomic profiling (CGP) to evaluate all classes of genomic alterations (GA). Tumor mutational burden (TMB) was determined on up to 1.1 Mbp of sequenced DNA and microsatellite instability (MSI) was determined on up to 114 loci. PD-L1 tumor cell expression was determined by IHC (Dako 22C3). Results: 1.3% of PC, 24.2% of BUC and 5.5% of ccRCC featured MTAP loss. There were no significant age or gender differences associated with MTAP loss. CDKN2A/B loss ranged from 94% in ccRCC to &gt; 99% in PC and BUC. The GA/tumor frequencies were similar when CDKN2A/B GA are excluded. In PC, GA in TP53, PTEN and BRCA1 were more frequent, while GA in AR, CDK12, RB1 and BRCA2 were less frequent in cases with MTAP loss. In BUC, GA in TSC1 and FGFR3 were more frequent and GA in RB1and TP53 were less frequent in cases with MTAP loss. In ccRCC, GA in NF2 were more frequent in cases with MTAP loss, while GA in VHL and PBRM1 were less frequent in cases with MTAP loss. “Targetable” kinase GA were rare in all groups, except for FGFR3 GA in MTAP loss BUC. Immunotherapy (IO) putative biomarkers varied among tumors, with MSI-high status less frequent and TMB ≥ 10 mut/Mb more frequent in BUC MTAP-intact than BUC with MTAP loss. PD-L1 expression was similar except for high PD-L1 expression more frequent in MTAP-intact BUC. Conclusions: When compared with PC and ccRCC, the clinical development of novel drugs, such as PRMT5 and MTA2 inhibitors in GUca will likely be focused on BUC given the 24% frequency of MTAP loss in that tumor type. CGP of PC, BUC and ccRCC reveal significant differences in GA in MTAP-intact and tumors with MTAP loss, which may impact future combinatorial clinical trial designs.[Table: see text]
Phosphatidylserine released from apoptotic cells in tumor induces M2‐like macrophage polarization through the PSR‐STAT3‐JMJD3 axis
Authors: Xiao Liang, Min Luo, Bin Shao, Jing‐Yun Yang, An Tong, Rui‐Bo Wang, Yan‐Tong Liu, Ren Jun, Ting Liu, Tao Yi, Xia Zhao, Yu‐Quan Wei, Xia‐Wei Wei
Journal: Cancer Communications (2022)

Abstract Background Understanding how the tumor microenvironment is shaped by various factors is important for the development of new therapeutic strategies. Tumor cells often undergo spontaneous apoptotic cell death in tumor microenvironment, these apoptotic cells are histologically co‐localized with immunosuppressive macrophages. However, the mechanism by which tumor cell apoptosis modulates macrophage polarization is not fully understood. In this study, we aimed to explore the tumor promoting effects of apoptotic tumor cells and the signal pathways involved. Methods Apoptotic cells and macrophages in tumors were detected by immunohistochemical staining. Morphological analysis was performed with Giemsa staining. Lipids generated from apoptotic cells were detected by liquid chromatography‐mass spectrometry. Phosphatidylserine‐containing liposomes were prepared to mimic apoptotic cells. The expression of protein was determined by real‐time PCR, immunohistochemistry enzyme‐linked immunosorbent assay and Western blotting. Mouse malignant ascites and subcutaneous tumor models were designed for in vivo analysis. Transgenic mice with specific genes knocked out and inhibitors specific to certain proteins were used for the mechanistic studies. Results The location and the number of apoptotic cells were correlated with that of macrophages in several types of carcinomas. Phosphatidylserine, a lipid molecule generated in apoptotic cells, induced polarization and accumulation of M2‐like macrophages in vivo and in vitro. Moreover, sustained administration of phosphoserine promoted tumor growth in the malignant ascites and subcutaneous tumor models. Further analyses suggested that phosphoserine induced a M2‐like phenotype in macrophages, which was related to the activation of phosphoserine receptors including T‐cell immunoglobin mucin 4 (TIM4) and the FAK‐SRC‐STAT3 signaling pathway as well as elevated the expression of the histone demethylase Jumonji domain‐containing protein 3 (JMJD3). Administration of specific inhibitors of these pathways could reduce tumor progression. Conclusions This study suggest that apoptotic cell‐generated phosphoserine might be a notable signal for immunosuppressive macrophages in tumors, and the related pathways might be potential therapeutic targets for cancer therapy.
Breast Risk Reduction
Authors: _ _
Journal: Journal of the National Comprehensive Cancer Network (2007)

Breast cancer is the most commonly diagnosed cancer in American women, with an estimated 214,640 cases and 41,430 deaths occurring in 2006. Estimating breast cancer risk for individual women is difficult, and most breast cancers are not attributable to risk factors other than female gender and increased age. Developing effective strategies for reducing breast cancer incidence is also difficult because few existing risk factors are modifiable and some potentially modifiable risk factors have social implications. Nevertheless, effective breast cancer risk reduction agents and strategies, such as tamoxifen, raloxifene, and risk reduction surgery, have been identified. These guidelines were developed to help women at increased risk for breast cancer and their physicians apply individualized strategies to reduce breast cancer risk. For the most recent version of the guidelines, please visit NCCN.org
Resuscitation After Myocardial Infarction
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Global Cardiovascular and Renal Outcomes of Reduced GFR
Authors: Bernadette Thomas, Kunihiro Matsushita, Kalkidan Hassen Abate, Ziyad Al-Aly, Johan Ärnlöv, Kei Asayama, Robert Atkins, Alaa Badawi, Shoshana H. Ballew, Amitava Banerjee, Lars Barregård, Elizabeth Barrett-Connor, Sanjay Basu, Aminu K. Bello, Isabela Bensenor, Jaclyn Bergstrom, Boris Bikbov, Christopher Blosser, Hermann Brenner, Juan-Jesus Carrero, Steve Chadban, Massimo Cirillo, Monica Cortinovis, Karen Courville, Lalit Dandona, Rakhi Dandona, Kara Estep, João Fernandes, Florian Fischer, Caroline Fox, Ron T. Gansevoort, Philimon N. Gona, Orlando M. Gutierrez, Samer Hamidi, Sarah Wulf Hanson, Jonathan Himmelfarb, Simerjot K. Jassal, Sun Ha Jee, Vivekanand Jha, Aida Jimenez-Corona, Jost B. Jonas, Andre Pascal Kengne, Yousef Khader, Young-Ho Khang, Yun Jin Kim, Barbara Klein, Ronald Klein, Yoshihiro Kokubo, Dhaval Kolte, Kristine Lee, Andrew S. Levey, Yongmei Li, Paulo Lotufo, Hassan Magdy Abd El Razek, Walter Mendoza, Hirohito Metoki, Yejin Mok, Isao Muraki, Paul M. Muntner, Hiroyuki Noda, Takayoshi Ohkubo, Alberto Ortiz, Norberto Perico, Kevan Polkinghorne, Rajaa Al-Radaddi, Giuseppe Remuzzi, Gregory Roth, Dietrich Rothenbacher, Michihiro Satoh, Kai-Uwe Saum, Monika Sawhney, Ben Schöttker, Anoop Shankar, Michael Shlipak, Diego Augusto Santos Silva, Hideaki Toyoshima, Kingsley Ukwaja, Mitsumasa Umesawa, Stein Emil Vollset, David G. Warnock, Andrea Werdecker, Kazumasa Yamagishi, Yuichiro Yano, Naohiro Yonemoto, Maysaa El Sayed Zaki, Mohsen Naghavi, Mohammad H. Forouzanfar, Christopher J.L. Murray, Josef Coresh, Theo Vos
Journal: Journal of the American Society of Nephrology (2017)

The burden of premature death and health loss from ESRD is well described. Less is known regarding the burden of cardiovascular disease attributable to reduced GFR. We estimated the prevalence of reduced GFR categories 3, 4, and 5 (not on RRT) for 188 countries at six time points from 1990 to 2013. Relative risks of cardiovascular outcomes by three categories of reduced GFR were calculated by pooled random effects meta-analysis. Results are presented as deaths for outcomes of cardiovascular disease and ESRD and as disability-adjusted life years for outcomes of cardiovascular disease, GFR categories 3, 4, and 5, and ESRD. In 2013, reduced GFR was associated with 4% of deaths worldwide, or 2.2 million deaths (95% uncertainty interval [95% UI], 2.0 to 2.4 million). More than half of these attributable deaths were cardiovascular deaths (1.2 million; 95% UI, 1.1 to 1.4 million), whereas 0.96 million (95% UI, 0.81 to 1.0 million) were ESRD-related deaths. Compared with metabolic risk factors, reduced GFR ranked below high systolic BP, high body mass index, and high fasting plasma glucose, and similarly with high total cholesterol as a risk factor for disability-adjusted life years in both developed and developing world regions. In conclusion, by 2013, cardiovascular deaths attributed to reduced GFR outnumbered ESRD deaths throughout the world. Studies are needed to evaluate the benefit of early detection of CKD and treatment to decrease these deaths.
Is endoscopic mucosal resection optimum for treating colonic angiodysplasia?
Authors: Sophie Geyl, Jérémie Albouys, Marion Schaefer, Hugo Lepetit, Romain Legros, Mathieu Pioche, Jérémie Jacques
Journal: Endoscopy (2022)

Colonic angiodysplasias are vascular malformations frequently responsible for recurrent bleeding, for which the gold standard endoscopic treatment is argon plasma coagulation (APC). However, APC can be risky, particularly in the right colon and in cases of large angiodysplasias. Indeed, secondary perforation caused by transmural necrosis due to the unpredictability of the destruction depth is a potentially life-threatening complication of APC in the right colon (prevalence 1 %) [1]. Moreover, APC frequently induces immediate bleeding and clot formation, reducing its efficacy and leading to a high rebleeding rate. Finally, the cost of the procedure is not negligible and patients suffering from bleeding often require urgent transfer to a specialist center.
A RIGHTEOUS VERDICT AGAINST AN ANTIVIVISECTIONIST.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Proctalgia Fugax
Authors: M. R. Ewing
Journal: BMJ (1953)

Pyrimethamine administered weekly in a dosage of 25 mg.afforded complete protection against overt malarial attack in a group of 14 non-immune subjects repeatedly exposed to mosquito infection by a West African strain of Plasmodium falciparum.The action appears to be that of a true causal prophylactic against this species of parasite.We wish to express our thanks to Dr.
Amenorrhoea
Authors: P. Hopkins
Journal: BMJ (1965)

after 14 days it had fallen to 60% with 10% of reticulocytes in the peripheral blood.Then the S.G.O.T. was 57 units; S.G.P.T. 44 units; total serum bilirubin 2.9 mg./100 ml.; conjugated bilirubin 2.3 mg./100 ml.The urine and faeces were returning to normal colour, the urine containing a marked excess of urobilinogen.
Roentgenographic evaluation of cervical spine trauma
Authors: O. P. Charlton
Journal: JAMA (1979)

A practical approach to the roentgenographic assessment of a patient suspected of having a cervical spine injury is described. Once positioned, the patient is not moved until substantial bony injury has been excluded. The major roentgenographic signs with differential diagnosis are briefly discussed using some illustrative roentgenograms. (<i>JAMA</i>242:1073-1075, 1979)